[Pathophysiological conditions progressing from impaired glucose tolerance: high blood pressure].
Katayama
Shigehiro
S
Division of Endocrinology and Diabetes, Department of Internal Medicine, Saitama Medical School.
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control; D018450:Disease Progression; D042783:Endothelial Cells / Q000502:physiology; D018149:Glucose Intolerance / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D007333:Insulin Resistance; D020738:Leptin / Q000502:physiology; D008019:Life Style; D009765:Obesity / Q000150:complications / Q000503:physiopathology
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D020738:Leptin